Hormone Receptor Expression Is Associated With a Unique Pattern of Metastatic Spread and Increased Survival Among HER2-Overexpressing Breast Cancer Patients

No abstract is available for this paper.

• Publication year

  2009

• Venue

  American Journal of Clinical Oncology

• Publication date

  2009-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/COC.0b013e3181967d72PMID 19564785
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potential role of HER-2; in primary breast tumor with bone metastasis.

  2006cited by this paper
• Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

  2006cited by this paper
• Brain metastases in patients with breast cancer: new horizons.

  2005cited by this paper
• Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

  2005cited by this paper
• Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.

  2005cited by this paper
• Correlation of Her‐2/neu Gene Amplification with Other Prognostic and Predictive Factors in Female Breast Carcinoma

  2005cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005influential reference
• The distinctive nature of HER2-positive breast cancers.

  2005cited by this paper
• Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.

  2005cited by this paper
• Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis.

  2004cited by this paper
• Risk factors for brain relapse in patients with metastatic breast cancer.

  2004cited by this paper
• Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment.

  2004cited by this paper
• Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): Results from Cancer and Leukemia Group B study 8461 and review of the literature

  2004cited by this paper
• Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer

  2004cited by this paper
• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  2004cited by this paper
• Brain metastases from breast cancer: identification of a high-risk group.

  2004cited by this paper
• Central nervous system metastases in patients with high‐risk breast carcinoma after multimodality treatment

  2004cited by this paper
• The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma

  2004cited by this paper
• Human Epidermal Growth Factor Receptor 2 Status Modulates Subcellular Localization of and Interaction with Estrogen Receptor α in Breast Cancer Cells

  2004cited by this paper
• Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma

  2003cited by this paper
• SDF-1alpha production is negatively regulated by mouse estrogen enhanced transcript in a mouse thymus epithelial cell line.

  2003cited by this paper
• SDF-1α production is negatively regulated by mouse estrogen enhanced transcript in a mouse thymus epithelial cell line

  2003cited by this paper
• Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells.

  2003cited by this paper
• Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

  2003cited by this paper
• Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.

  2002cited by this paper
• Involvement of chemokine receptors in breast cancer metastasis

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• The n e w e n g l a n d j o u r n a l of m e d i c i n e

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer

  2000cited by this paper
• Molecular mechanisms underlying ErbB2/HER2 action in breast cancer

  2000cited by this paper
• AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen

  2000cited by this paper
• Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers.

  1996cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• Significance of estrogen and progesterone receptors, disease‐free interval, and site of first metastasis on survival of breast cancer patients

  1985cited by this paper
• Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma.

  1984cited by this paper

• Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer

  2024cites this paper
• Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer.

  2024cites this paper
• Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy

  2023cites this paper
• Breast cancer liver metastasis: Pathogenesis and clinical implications

  2022cites this paper
• Risk factors for breast cancer brain metastases: a systematic review

  2020cites this paper
• Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database

  2020cites this paper
• Assessment of the predictive role of oestrogen and progesterone receptor status in breast cancer patients treated with neoadjuvant chemotherapy: A retrospective analysis for 689 patients

  2020cites this paper
• De novo metastasis in breast cancer: occurrence and overall survival stratified by molecular subtype

  2017cites this paper
• Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results

  2017cites this paper
• Pattern of metastatic spread and subcategories of breast cancer

  2016cites this paper
• Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR−/HER2+ breast cancers

  2015cites this paper
• Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients

  2015cites this paper
• Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients

  2015cites this paper
• Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study

  2012cites this paper